AML patients (total 129; median age ¼ 50 years; range 16-72) in first CR received BU and melphalan (BU/Mel) as conditioning regimen before auto-SCT. In all, 82 patients (63.6%) received PBSCs and 47 patients (36.4%) received BM cells. The distribution of cytogenetic categories was conventionally defined as favorable (15.5%), intermediate (60.1%) and unfavorable (24.3%). With a median followup of 31 months, the 8-year projected OS and disease-free survival (DFS) was 62 and 56% for the whole population, respectively. The relapse rate was 46% and the non-relapse mortality was 4.65%. Although PBSC transplantation led to a faster hematological recovery than BM transplantation, in univariate analysis the stem cell source, cytogenetics and different BU formulations did not significantly affect OS and DFS, whereas age and the number of postremission chemotherapy cycles did have a significant effect on the clinical outcome. Multivariate analysis identified age o55 years as the only important independent predictor for OS and DFS. Our data suggest that BU/Mel, being associated with a low toxicity profile (mainly mucositis) and mortality, is an effective conditioning regimen even for high-risk AML patients in first CR undergoing auto-SCT.
Introduction
Most of the patients with AML achieve CR after induction/ consolidation therapy. 1 However, the majority relapses without any further post-remission treatment. Therefore, post-remission therapeutic strategies have been progressively intensified, [2] [3] [4] including high-dose chemotherapy followed by infusion of allogeneic or autologous stem cells. The role of auto-SCT in the treatment of patients with AML in first CR remains unsettled. Although allo-SCT is considered the most effective anti-leukemic treatment available for young patients with high-risk AML in first CR, 1, 2 there is a certain degree of controversy on the best therapeutic approach for other patient populations. The results from early phase III trials have generally shown that auto-SCT results in a lower relapse rate than conventional chemotherapy that results in a modest improvement in the disease-free survival (DFS). [4] [5] [6] However, there was no apparent improvement in OS, probably because of the slightly increased mortality associated with the use of BMderived cells. From this point of view, autologous, mobilized PBSC transplantation offers a much faster hematopoietic recovery and is associated with reduced morbidity and treatment-related mortality (TRM). Thus, several retrospective studies have shown improved longterm results when autologous PBSCs were reinfused as compared with BM cells. [7] [8] [9] Few phase III studies have also addressed the role of allo-SCT and auto-SCT in young AML patients in first CR with respect to cytogenetic categories. [10] [11] [12] Suciu et al. 10 showed similar DFS rate for good/intermediate-risk patients receiving either allo-SCT or auto-SCT, whereas auto-SCT resulted in a lower DFS rate in AML patients with unfavorable cytogenetics because of the higher relapse rate. Moreover, the Southwest Oncology Group/Eastern Cooperative Oncology Group showed that patients with favorable cytogenetics had significantly better outcome after auto-SCT and allo-SCT than after chemotherapy alone, whereas patients with unfavorable cytogenetics did better with allo-SCT. 11 The most effective conditioning regimen before auto-SCT remains controversial. The anti-leukemic activity of the combination of BU and cyclophosphamide (BU/Cy) is well established before auto-SCT, although the extra-hematologic toxicity is significant and the highly immunosuppressive potential of the conditioning regimen delays immunologic reconstitution. Moreover, the relapse rate is often in the range of 45-50% even in young patients without poor risk characteristics. A large number of studies have analyzed alternative preparative regimens, including TBI with cyclophosphamide, BU with etoposide and TBI with cyclophosphamide and etoposide, without any relevant superiority of one regimen over the others. [5] [6] [7] Therefore, there is a need to analyze novel conditioning regimens by coupling high anti-leukemic activity with low extra-hematological toxicity.
Melphalan (Mel) is a bifunctional alkylator with a broad spectrum of activity in a variety of hematological malignancies. Mel can be safely administered to heavily pretreated patients, with myelosuppression being its main toxicity. [13] [14] [15] [16] [17] [18] [19] High-dose Mel with PBSCs support has been used extensively in the treatment of lymphoid malignancies, such as multiple myeloma, 14 relapsed or refractory lymphoma, 15 acute lymphoblastic and myeloblastic leukaemia. 16, 17 Moreover, high-dose Mel achieved results comparable with those observed with TBI-or BU-containing regimens in childhood AML in first CR. 13 More recently, Mel has been used in combination with fludarabine for reduced-intensity conditioning before allo-SCT. 18, 19 In this study, we report the results of 129 patients with AML in first CR who underwent auto-SCT in 10 different Italian transplant centers. AML patients were conditioned with BU/Mel with dose-adjustment according to age. We then analyzed the results according to the most important factors affecting OS and DFS, including stem cell source, risk group, cytogenetic categories, post-remission chemotherapy, age and different BU formulations. Our data indicate that BU/Mel, being associated with a low toxicity profile and TRM, is an effective conditioning regimen for high-risk AML patients in first CR undergoing auto-SCT.
Patients and methods

Patients
This is a clinical study involving 10 different Italian transplant centers. In total, 129 consecutive patients were studied. All patients had a diagnosis of AML according to French-American-British system of classification. 20 The median age of study patients was 50 years (range 21 The patients were classified as high risk (57/116 evaluable patients; total 49.1%) when the WBC count at diagnosis was higher than 30 Â 10 9 /l and/or cytogenetics was unfavorable and/or in the case of secondary AML; otherwise they were considered to be of standard risk (59/116; 50.9%). The number of chemotherapy regimens before auto-SCT was evaluable in 122 patients; 44 patients (36%) received two chemotherapy courses and 78 patients (64%) received more than two cycles before transplantation. The schedules for induction and consolidation treatment were different according to the single institution protocols.
Conditioning regimen
All patients underwent the same BU/Mel conditioning regimen with dose adjustment depending on age. Patients under 60 years of age (total 97, 75.2%) received Mel at 140 mg/m 2 (1 h infusion for 1 day), combined with BU at 16 mg/kg orally (1 mg/kg every 6 h/day for 4 days; total patients 78, 80.4%) or 12.8 mg/kg i.v. (Busilvex, Pierre Fabre, Boulogne, France) (0.8 mg/kg every 6 h/day for 4 days; total patients 19, 19.6%). Patients older than 60 years (total 32, 24.8%) received Mel at 120 mg/m 2 (1 h infusion for 1 day) and BU at 12 mg/kg orally (1 mg/kg every 6 h/day for 3 days; total patients 17, 53%) or 9.6 mg/kg i.v. (0.8 mg/kg every 6 h/day for 3 days; total patients 15, 47%). 
Stem cell source
Hematopoietic recovery
Time to neutrophil and plt recovery was defined as the number of days to achieve an ANC higher than 0.5 Â 10 9 /l (first of 3 consecutive days) and an unsupported plt count higher than 20 and 50 Â 10 9 /l.
Supportive care
The supportive care during auto-SCT included the use of reverse isolation rooms, prophylactic red blood cell and plt transfusion, antibacterial and antifungal gastrointestinal decontamination and the empirical use of i.v. antibiotics if the patient became febrile, according to each transplant center guidelines.
Toxicity
All cases of early post-transplant non-hematologic organ disfunction were considered regimen-related toxicity unless they could clearly be explained otherwise (for example, renal disfunction markedly improved after discontinuation of nephrotoxic antibiotics). The regimen-related toxicity was evaluated according to the World Health Organization grading scale (0-4) 23 by considering four main extrahematologic toxicity: mucositis, renal, hepatic and lung toxicity.
Statistical analysis
The OS and DFS curves were calculated according to Kaplan and Meier. 24 OS was defined as the time from CR to death or last contact with the patient. DFS was calculated from the date of CR to the date of relapse or death, or last contact with patient in continuous CR. The time to relapse was calculated as DFS, but the follow-up of patients who died in CR and those who relapsed were censored at that time for this analysis. Comparison of the survival curves in univariate analysis was performed using log-rank test. 25 Multivariate analysis was performed using a forward stepwise Cox proportional hazards model. The prognostic factors analyzed for OS, DFS and time to relapse were age, the number of pre-auto-SCT chemotherapy cycles (2 cycles vs 42 cycles) and BU formulation (oral vs i.v.). Differences with P-values o0.05 were considered statistically significant. The statistical analyses were computed using SPSS statistical software (SPSS Inc., Chicago, IL, USA).
Results
Hematological recovery
Hematological recovery was evaluable in 123 patients. Six patients did not achieve a full granulocyte recovery and died within the first 3 months from stem cell infusion.
The median time to granulocyte recovery was 14 days (range 8-121) after transplantation. The median time to plt recovery (platelet value 420 Â 10 9 /l) was 18 days (10-255) and to a plt value 450 Â 10 9 /l was 44 days (range 10-308). PBSC transplantation led to a faster hematological recovery compared with BM transplantation and the difference was highly statistically significant: the time to granulocyte recovery was 12 days after PBSC transplantation vs 28 days after BM transplantation (P ¼ 0.00001); the time to plt recovery was 16 days in the PBSC group compared with 53 days in the BM group (P ¼ 0.00001).
Documented infectious complications occurred in 45.8% of patients. Overall, the median time to hospital discharge after auto-SCT was 22 days (range 10-90): PBSC recipients had a significantly shorter hospitalization (median 17 days; range 10-41) as compared with BM patients (26.5 days; range 13-90; Po0.0003). In all, 78 patients received G-CSF at the dose of 5 mg/kg/day after auto-SCT to accelerate granulocyte recovery, with a median duration of 9 days (range 1-30). The incidence of TRM within the first 3 months after auto-SCT was 4.65%.
Toxicity profile
In total, 129 patients were evaluable for extra-hematological toxicity, graded according to the World Health Organization (Table 2 ). Both hepatic and pulmonary grade 3-4 toxicity were observed in three patients each. Renal toxicity was negligible. The main extra-hematological toxicity was mucositis: 42 patients showed grade 1-2 mucositis and 57 patients showed grade 3-4. The incidence of ulcerative mucositis (grade 2-4) was 65.9% (85 patients) and the incidence of severe mucositis (grade 3-4) was 47.9% (57 patients). It is noteworthy that the incidence of grade 3-4 toxicity (including mucositis) was not different according to the different BU formulation used (that is, oral vs i.v.; Table 2 ).
Relapse rate, disease-free survival (DFS) and OS The median time from CR to auto-SCT was 5 months (range 1-37 months). The median follow-up from transplantation was 31 months (range 5-141). The 8-year projected OS, DFS and time to relapse for the whole population was 62% (95% confidence interval: 71.68-52.32), 56% (95% confidence interval: 65.8-46.2) and 46% (95% confidence interval: 56.62-36.38), respectively ( Figure 1 ).
Prognostic factors and clinical parameters
In univariate analysis, the stem cell source and high-risk disease did not significantly affect OS and DFS. This latter finding was also confirmed when the data were analyzed according to the cytogenetic categories alone (data not shown). The patients who underwent two or more post-remission chemotherapy cycles showed a significantly better OS and DFS than patients treated with only one cycle (OS 74.3 vs 61.3%, Po0.05; DFS 68 vs 54.5%, Po0.05) (Figures 2a and b) .
There was a significantly better OS and DFS in younger patients than in elderly patients (cut-off age considered: 60 years and 55 years). This difference was more evident with the cut-off age of 55 years (OS 79.5 vs 55%, Po0.000; DFS 72.4 vs 50%, Po0.0000, Figures 3a and b) . Specifically, out of 51 patients older than 55 years, 22 died (18 because of disease relapse and 4 from TRM).
The use of i.v. BU did not significantly affect OS, whereas DFS was significantly lower as compared with oral formulation (data not shown).
The multivariate analysis identified age o55 years as the only important independent predictor for OS, DFS and time to relapse (Table 3) .
Discussion
We report in this study, for the first time, a large multicenter Gruppo Italiano Trapianto di Midollo Osseo study of AML patients in first CR undergoing auto-SCT conditioned with BU/Mel. The clinical characteristics of study patients are roughly comparable with those of AML patients included in previous multicenter studies with regard to prognostic factors, such as WBC number at diagnosis, and the number of induction and consolidation chemotherapy courses to achieve and maintain CR. [26] [27] [28] Regarding the distribution into cytogenetic categories, we included a higher number of patients in the intermediate group (50-65% in previous studies vs 74% in our study), a smaller number of patients in the favorable group (20-30% vs 15.5%) and a comparable number in the unfavorable group (10-25 vs 24.4% ).
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When we analyzed the short-term outcome, we found that, similar to earlier studies, [7] [8] [9] PBSC transplantation resulted in a significant shorter time to hematological reconstitution as compared with BM grafts. 29, 30 However, the stem cell source did not significantly affect the clinical outcome of AML patients, as we have already showed in our previous long-term single-center analysis. 9 It is noteworthy that a recent registry European Cooperative Group for Blood and Marrow Transplantation study has shown a higher relapse rate after PBSC transplantation. 31 In our study, this finding may be partially related to the low TRM reported here (4.65%), regardless of whether BM or mobilized PB was used. In this view, BU/Mel conditioning regimen seemed to be well tolerated. No significant impairment of hepatic, renal and pulmonary function and no episode of liver sinusoidal obstructive syndrome were observed after auto-SCT. As shown earlier 32 when Mel was used alone or in combination with TBI, oral mucositis was the only relevant extra-hematological adverse event with no difference in the toxicity profile of the two different BU formulations used in this study. Given the high incidence of oral mucositis after BU/Mel conditioning regimen, the possibility of using the N-terminal, truncated version of keratinocyte growth factor, palifermin, should be considered as a valuable option. Recently, in a phase III trial, palifermin has been shown to reduce the incidence and severity of oral mucositis in patients undergoing auto-SCT after conditioning therapy with a high dose of fractionated TBI and chemotherapy. 33 As for the anti-leukemic activity, the use of i.v. BU resulted in a lower DFS 34 in univariate, but not multivariate, analysis and this finding may be because of the higher percentage of young patients who had received oral BU (82 vs 55%). Overall, our study showed a promising 8-year projected OS and DFS of 62 and 56%, respectively, for the whole population, without any statistical difference between different cytogenetic categories and risk groups. In most of the previous large studies [35] [36] [37] cytogenetics has emerged as the most important prognostic factor: patients with a favorable karyotype had better OS and lower probability of relapse than patients with unfavorable karyotype. [4] [5] [6] 26, [35] [36] [37] Taken together, the earlier studies indicated that in good-risk patients, allo-SCT induced a lower relapse rate but it was associated with a higher TRM as compared with auto-SCT. On the other hand, the results of auto-SCT for AML patients in CR1 with favorable cytogenetics were consistently better than those observed with non-ablative chemotherapy. [3] [4] [5] Given these results, auto-SCT may be the treatment of choice in this group of patients. 26, [35] [36] [37] Gorin et al. 38 reported, in a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation, the outcome after auto-SCT and allo-SCT in first CR of AML carrying mutations of the core binding factor (CBF), such as inversion 16 and translocation, t(8;21) . Among all patients with inversion 16, this study reported a 5-year leukemia-free survival after auto-SCT and allo-SCT of 59 and 66%, respectively (P ¼ 0.5); in the group of patients with t(8;21), the 5-year leukemia-free survival rates were 60 and 66%, respectively (P ¼ 0.69). The relapse incidence rates after auto-SCT and allo-SCT showed a statistically significant difference only among patients with t(8;21). TRM was lower in auto-SCT recipients in both the cytogenetic groups. In this study, auto-SCT has resulted in outcomes identical to allo-SCT, thus remaining a valid treatment option for patients with core binding factor AML. 38 Conversely, for patients with poor-risk cytogenetics, the outcome with both chemotherapy and auto-SCT seemed to be poor and allo-SCT emerged as the treatment of choice, [3] [4] [5] 35, 36 whereas the outcome of patients with intermediate-risk AML remains controversial. 35 In our study, BU/Mel preparative regimen induced a remarkable 8-year projected DFS 450% in poor-and intermediaterisk cytogenetic categories. This finding was rather surprising; therefore, we also analyzed the data by applying the more restrictive classifications of the Southwest Oncology Group and the Medical Research Council; 11 however, they include only 11 and 7 patients, respectively, in the unfavorable risk group. Owing to the limitations due to a statistical analysis evaluating a small number of patients, we did not observe any difference in the outcome of this patient population as compared with good-and intermediate-risk groups. Therefore, auto-SCT may be a valid option for AML patients in CR1, despite risk group and karyotype.
In the univariate analysis, the age of AML patients at transplant and the number of consolidation cycles (X2 cycles vs o2 cycles) before auto-SCT were significant prognostic factors for both OS and DFS.
However, in multivariate analysis, only the age emerged as the most important prognostic factor for the clinical outcome with a cut-off limit of 55 years. The lack of significance of the post-remission therapy can be explained by a selection bias that excludes early relapses from the group of patients undergoing auto-SCT after 1 course of consolidation. It is noteworthy that OS and DFS in the elderly (that is, AML patients either 455 or4 60 years) seemed to be better than those routinely observed with chemotherapy alone. Furthermore, the hospital stay, infectious complications and the kinetics of engraftment were comparable with those observed in younger patients (data not shown). Although auto-SCT represents, at the moment, a therapeutic option for a minority of elderly AML patients and the selection bias should be considered, 39 the relatively low toxicity profile of the age-adjusted BU/Mel combination and its promising anti-leukemic effects, makes this strategy also attractive in a group of patients in whom prognosis is usually poor. Burnett and Mohite 40 reported a median OS of 14.4 months and o10% DFS at 3 years in the multicenter, nonrandomized, phase II trial cancer therapy evaluation program, CTEP-20, whereas Clavio et al. 41 published a median OS of 8 months and a median DFS of 7 months, after 24-month median follow-up, in an Italian multicenter study.
In conclusion, our multicenter study suggests that BU/ Mel myeloablative chemotherapy with autologous stem cell support is an effective option for patients with AML in CR1 in all risk groups and cytogenetic categories. Thus, auto-SCT should still be considered as a valuable approach for AML patients in CR1 without a human leukocyte antigen-matched sibling donor.
